ABVX

Abivax SA (ABVX) | Rumor.io

Abivax SA

ABVX

Attention (50-day avg)0.03%

Attention rank (50-day avg)#242

Bullish sentiment (50-day avg)37%

Price to earnings ratio-20

Market capitalization8.5B

Earnings per share-6.11

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-336.1M

Social

What share of all stock conversation is about ABVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0.03% -0.02	0.03% +0.01	0.02% +0.01

Sep 28

Abivax S.A. (ABVX) has reported successful Phase 3 results for its ulcerative colitis drug, obefazimod, which could lead to a takeover or significant price increase.
The company has raised $920M, extending its cash runway to Q4 2029, which de-risks the company and makes it more attractive to investors.
The recent data readouts and Phase 3 results have sparked speculation and optimism among investors, with some predicting a breakout and fresh highs, while others warn of a potential slide back to the mid-$80s.

Generated by AI

Sentiment

Of the messages about ABVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	94.34% +12.12	37.49% +15.35	33.98% -8.31	56.39% -31.47
Bearish	5.66% -12.12	62.51% -15.35	66.02% +8.31	43.61% +31.47

Bullish· Jul 6

$ABVX's PT was raised to €141 at Oddo BHF, and to $140 at Wedbush, indicating a strong potential for growth.
The stock's short interest could add significant upside momentum, making it a potential buying opportunity.
A nearly $1 billion offering could lead to increased liquidity and further price appreciation, making $ABVX a promising investment.

Bearish· Sep 22

The company's efficacy results were disappointing, with a -30% drop in the stock price after a safety scare was debunked.
The company's management has been criticized for engineering two 50% drops in the stock price within three months, despite having a promising disease drug for UC.
The stock price has been drifting lower, with the potential to reach the 80s range, and the company's overvaluation has been highlighted, with one post calling it "shit" and another describing it as "dead money".

Generated by AI

Topics

Of the messages about ABVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	92.31%	62.78%	70.87%	39.13%
Technical Analysis	7.69%	30.56%	8.98%	2.71%
Analysts	0%	4.44%	16.13%	29.34%
Macro	0%	2.22%	0.22%	26.72%
Earnings	0%	0%	3.79%	0.39%
Controversies	0%	0%	0%	1.71%

Analysts· Jun 30

BTIG raised the price target on Abivax to $175 from $150, maintaining a Buy rating, citing additional safety data from the ABTECT Maintenance Part 2 update.
Guggenheim reiterated a Buy rating and $175 price target on Abivax, citing 44-week maintenance data for obefazimod in ulcerative colitis, with no new safety signals reported.
Wedbush raised the price target on Abivax to $110 from $90, maintaining a Neutral rating, citing updated safety and efficacy data from the ABTECT study, but remaining concerned about the potential for a Black Box warning.

Announcements· Jul 2

Abivax S.A. (ABVX) has multiple interested buyers, according to Reuters.
The company plans to meet with the FDA on July 30th for a pre-NDA meeting ahead of an expected NDA submission in 4Q26.
Stifel has lifted its estimate on obefazimod peak sales to 4 billion EURO, up from 2.5 billion EURO previously.

Generated by AI

Community

Of the messages about ABVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	84.13%	79.16%	85.55%	78.53%
Newcomers	15.87%	20.84%	14.45%	21.47%

Regulars· Sep 28

The recent raises by Abivax and NKTR should insulate them from rising interest rates, and sitting on a large cash pile has a positive effect.
A patient in durable remission may stay with Abivax for years, and the difference in this UEG data may be worth considering, but it's unclear what that difference is worth.
Abivax may be oversold, and it's time to add some, with the stock feeling like buyers are slowly taking control.

Newcomers· Sep 22

The Wedbush analyst has cut the price target for $ABVX, citing a need to adjust the target due to the stock's potential to drop below the analyst's price target.
Abivax reported zero revenue and a Q2 net loss of €117.4 million, heavily impacted by a non-cash loss from repurchasing its royalty certificates, but the company's earnings raise secures its runway.
$ABVX's recent price drop has been seen as a buying opportunity by some investors, with one user expressing satisfaction with their decision to buy the stock at a lower price, despite it not making sense to them.

Generated by AI

ABIVAX Société Anonyme (ENXTPA:ABVX) has just paired deeper operating cash use and wider losses with fresh leadership hires and extended funding, creating a complex backdrop for anyone tracking the stock today. Recent moves have come against a tougher tape for ABIVAX Société Anonyme, with the share price down 28.78% year to date and 15.91% over 30 days, even as the 1 year total shareholder return of 16.50% and the very large 3 year total shareholder return of 446.00% point to longer term...

3d agoYahoo Finance

ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers

ABIVAX Société Anonyme (ENXTPA:ABVX) has appointed a new Chief Medical Officer and a new Chief Technical Officer. The fresh leadership roles are focused on medical strategy, product development and technical operations across Abivax SA's pipeline. The appointments are intended to support the firm's efforts around clinical programs and preparation for potential commercialization activities. The appointment of a new Chief Medical Officer and Chief Technical Officer should not be the only...

3d agoYahoo Finance

ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?

4d agoYahoo Finance

Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts (NASDAQ:ABVX)

Abivax is advancing obefazimod for ulcerative colitis and Crohn’s, with recent safety concerns now largely addressed. Read more on ABVX stock here.

6d agoSeeking Alpha

These Analysts Slash Their Forecasts On Abivax Following H1 Results - Abivax (NASDAQ:ABVX)

Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.

7d agoBenzinga

Wedbush Cuts Price Target on Abivax to $118 From $160, Keeps Neutral Rating

Abivax (ABVX) has an average rating of buy and mean price target of $164.20, according to analysts p

8d agoYahoo Finance

Also Discussed

Investors talking about ABVX also mention

#	Name	Attention
1	Nektar TherapeuticsNKTR	0.08%+0.03
2	Revolution Medicines, Inc.RVMD	0.01%-0.01
3	Apogee Therapeutics, Inc. - Common StockAPGE	0%0
4	uniQure N.V.QURE	0.02%+0.01
5	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
6	Edgewise Therapeutics Inc.EWTX	0%new
7	Spruce Biosciences, Inc.SPRB	0%0
8	Celcuity Inc.CELC	0%0
9	Replimune Group, Inc.REPL	0%0
10	Crinetics Pharmaceuticals IncCRNX	0%new

Abivax SA

Healthcare
Biotechnology

Abivax SA Sponsored ADR is a biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to help stabilize the immune response in chronic inflammatory diseases. The company’s lead program centers on obefazimod, a clinical-stage candidate being studied for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. Abivax SA Sponsored ADR operates as a sponsored American Depositary Receipt representing the company’s ordinary shares, giving U.S. investors access to a France-based biopharmaceutical developer. Its current work is centered on clinical research, drug development, and advancing treatments aimed at complex immune-mediated conditions. Based in Paris, Abivax SA remains positioned within the global biotechnology market as a specialist in immunology-focused therapies and late-stage clinical development.

Website

Location

7-11 boulevard Haussmann

Paris, 75009

France

Social

What share of all stock conversation is about ABVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0.03% -0.02	0.03% +0.01	0.02% +0.01

Sep 28

Abivax S.A. (ABVX) has reported successful Phase 3 results for its ulcerative colitis drug, obefazimod, which could lead to a takeover or significant price increase.
The company has raised $920M, extending its cash runway to Q4 2029, which de-risks the company and makes it more attractive to investors.
The recent data readouts and Phase 3 results have sparked speculation and optimism among investors, with some predicting a breakout and fresh highs, while others warn of a potential slide back to the mid-$80s.

Generated by AI

Sentiment

Of the messages about ABVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	94.34% +12.12	37.49% +15.35	33.98% -8.31	56.39% -31.47
Bearish	5.66% -12.12	62.51% -15.35	66.02% +8.31	43.61% +31.47

Bullish· Jul 6

$ABVX's PT was raised to €141 at Oddo BHF, and to $140 at Wedbush, indicating a strong potential for growth.
The stock's short interest could add significant upside momentum, making it a potential buying opportunity.
A nearly $1 billion offering could lead to increased liquidity and further price appreciation, making $ABVX a promising investment.

Bearish· Sep 22

The company's efficacy results were disappointing, with a -30% drop in the stock price after a safety scare was debunked.
The company's management has been criticized for engineering two 50% drops in the stock price within three months, despite having a promising disease drug for UC.
The stock price has been drifting lower, with the potential to reach the 80s range, and the company's overvaluation has been highlighted, with one post calling it "shit" and another describing it as "dead money".

Generated by AI

Topics

Of the messages about ABVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	92.31%	62.78%	70.87%	39.13%
Technical Analysis	7.69%	30.56%	8.98%	2.71%
Analysts	0%	4.44%	16.13%	29.34%
Macro	0%	2.22%	0.22%	26.72%
Earnings	0%	0%	3.79%	0.39%
Controversies	0%	0%	0%	1.71%

Analysts· Jun 30

BTIG raised the price target on Abivax to $175 from $150, maintaining a Buy rating, citing additional safety data from the ABTECT Maintenance Part 2 update.
Guggenheim reiterated a Buy rating and $175 price target on Abivax, citing 44-week maintenance data for obefazimod in ulcerative colitis, with no new safety signals reported.
Wedbush raised the price target on Abivax to $110 from $90, maintaining a Neutral rating, citing updated safety and efficacy data from the ABTECT study, but remaining concerned about the potential for a Black Box warning.

Announcements· Jul 2

Abivax S.A. (ABVX) has multiple interested buyers, according to Reuters.
The company plans to meet with the FDA on July 30th for a pre-NDA meeting ahead of an expected NDA submission in 4Q26.
Stifel has lifted its estimate on obefazimod peak sales to 4 billion EURO, up from 2.5 billion EURO previously.

Generated by AI

Community

Of the messages about ABVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	84.13%	79.16%	85.55%	78.53%
Newcomers	15.87%	20.84%	14.45%	21.47%

Regulars· Sep 28

The recent raises by Abivax and NKTR should insulate them from rising interest rates, and sitting on a large cash pile has a positive effect.
A patient in durable remission may stay with Abivax for years, and the difference in this UEG data may be worth considering, but it's unclear what that difference is worth.
Abivax may be oversold, and it's time to add some, with the stock feeling like buyers are slowly taking control.

Newcomers· Sep 22

The Wedbush analyst has cut the price target for $ABVX, citing a need to adjust the target due to the stock's potential to drop below the analyst's price target.
Abivax reported zero revenue and a Q2 net loss of €117.4 million, heavily impacted by a non-cash loss from repurchasing its royalty certificates, but the company's earnings raise secures its runway.
$ABVX's recent price drop has been seen as a buying opportunity by some investors, with one user expressing satisfaction with their decision to buy the stock at a lower price, despite it not making sense to them.

Generated by AI

Abivax SA

Social

Sep 28

Bullish· Jul 6

Bearish· Sep 22

Analysts· Jun 30

Announcements· Jul 2

Regulars· Sep 28

Newcomers· Sep 22

ABIVAX Société Anonyme (ENXTPA:ABVX) Just Gave Investors Something To Think About

ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers

ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?

Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts (NASDAQ:ABVX)

These Analysts Slash Their Forecasts On Abivax Following H1 Results - Abivax (NASDAQ:ABVX)

Wedbush Cuts Price Target on Abivax to $118 From $160, Keeps Neutral Rating

Also Discussed

Abivax SA

Company Information

Location

ABIVAX Société Anonyme (ENXTPA:ABVX) Just Gave Investors Something To Think About

ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers

ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?

Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts (NASDAQ:ABVX)

These Analysts Slash Their Forecasts On Abivax Following H1 Results - Abivax (NASDAQ:ABVX)

Wedbush Cuts Price Target on Abivax to $118 From $160, Keeps Neutral Rating

Also Discussed

Social

Sep 28

Bullish· Jul 6

Bearish· Sep 22

Analysts· Jun 30

Announcements· Jul 2

Regulars· Sep 28

Newcomers· Sep 22